Mercados españoles cerrados

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
418,75+1,43 (+0,34%)
A partir del 03:45PM EDT. Mercado abierto.

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo5400

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman92,93k11,49M1956
Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director5,22MN/A1974
Mr. Charles F. Wagner Jr.Executive VP & CFO2,06MN/A1968
Mr. Stuart A. Arbuckle B.Sc.Executive VP & COO2,7M1,26M1966
Dr. David M. Altshuler M.D., Ph.D.Executive VP & Chief Scientific Officer2,03M3,09M1965
Ms. Kristen C. AmbroseSenior VP & Chief Accounting OfficerN/AN/A1977
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/AN/AN/A
Susie LisaSenior Vice President of Investor RelationsN/AN/AN/A
Mr. Jonathan Biller J.D.Executive VP & Chief Legal OfficerN/AN/A1964
Ms. Nina DevlinSenior VP & Chief Communications OfficerN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Vertex Pharmaceuticals Incorporated, a día 1 de marzo de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 7; Derechos de los accionistas: 6; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.